| P/E (FY) | — | Sales (TTM) | $32.7M |
| Earnings (TTM) | -$19.5M | ROE | −121.11% |
| Net Margin | −96.85% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 162.30% |
| Market Cap | $2.87B | Trading Days | 2142 |
| 52W High | 45.50 |
| 52W Low | 4.97 |
| % Off High | −33.52% |
| YTD | 230.68% | 1Y | 23.00% |
| 3Y | −73.73% | 5Y | −90.81% |
| Since incept. (ann.) | −27.38% |
| Ann. Volatility (1Y) | 194.35% | Ann. Volatility (3Y) | 144.53% |
| Sharpe (1Y) | 0.87 | Sharpe (3Y) | 0.31 |
| Max Drawdown (1Y) | −80.89% | Max Drawdown (3Y) | −95.39% |
| Beta (3Y, vs SPY) | 2.91 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| MBX | MBX Biosciences, Inc. | $2.86B | — |
| IRON | Disc Medicine, Inc. | $2.85B | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | $2.77B | — |
| ATAI | AtaiBeckley Inc. | $2.64B | — |
| IMNM | Immunome Inc. | $2.63B | — |
| TRVI | Trevi Therapeutics, Inc. | $2.62B | — |
| GRTX | Galera Therapeutics, Inc. | $2.61B | 25.4 |
| IDYA | IDEAYA Biosciences, Inc. | $3.18B | — |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.56B | — |
| ELVN | Enliven Therapeutics, Inc. | $3.27B | — |
| NRIX | Nurix Therapeutics, Inc. | $2.51B |
| — |
| PBH | Prestige Consumer Healthcare Inc. | $2.45B | 13.2 |
